Hologic Inc. (NASDAQ:HOLX)‘s stock had its “buy” rating reaffirmed by Evercore ISI in a research report issued on Saturday. They currently have a $43.00 target price on the stock. Evercore ISI’s target price indicates a potential upside of 11.83% from the company’s current price.
A number of other research analysts have also commented on HOLX. Jefferies Group reaffirmed a “buy” rating and set a $42.00 price target on shares of Hologic in a research report on Tuesday, June 21st. Bank of America Corp. reaffirmed a “buy” rating on shares of Hologic in a research report on Wednesday, June 22nd. Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research report on Friday, July 1st. Barclays PLC reissued a “hold” rating and issued a $42.00 target price on shares of Hologic in a research report on Sunday, July 10th. Finally, Piper Jaffray Cos. set a $40.00 target price on Hologic and gave the stock a “hold” rating in a research report on Monday, July 25th. They noted that the move was a valuation call. Six analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Hologic has a consensus rating of “Buy” and an average price target of $42.76.
Shares of Hologic (NASDAQ:HOLX) traded up 0.34% on Friday, hitting $38.45. The company had a trading volume of 1,547,204 shares. The stock has a market capitalization of $10.67 billion, a PE ratio of 42.39 and a beta of 1.00. Hologic has a 52 week low of $31.84 and a 52 week high of $41.66. The firm’s 50 day moving average price is $38.49 and its 200-day moving average price is $36.36.
Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.03. The business earned $717.40 million during the quarter, compared to analyst estimates of $703.66 million. Hologic had a return on equity of 26.25% and a net margin of 9.39%. Hologic’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.43 EPS. Analysts forecast that Hologic will post $1.94 earnings per share for the current fiscal year.
In related news, VP Karleen Marie Oberton sold 31,470 shares of Hologic stock in a transaction on Monday, October 10th. The stock was sold at an average price of $40.00, for a total transaction of $1,258,800.00. Following the transaction, the vice president now directly owns 17,005 shares in the company, valued at $680,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Nancy Leaming sold 8,179 shares of Hologic stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $37.00, for a total value of $302,623.00. Following the transaction, the director now owns 67,140 shares in the company, valued at $2,484,180. The disclosure for this sale can be found here. 0.84% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in HOLX. Panagora Asset Management Inc. increased its position in Hologic by 247.3% in the first quarter. Panagora Asset Management Inc. now owns 1,682,853 shares of the company’s stock valued at $58,058,000 after buying an additional 1,198,338 shares during the period. AMP Capital Investors Ltd increased its position in Hologic by 33.8% in the first quarter. AMP Capital Investors Ltd now owns 222,865 shares of the company’s stock valued at $7,690,000 after buying an additional 56,357 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in Hologic during the first quarter valued at $689,000. Oakbrook Investments LLC bought a new position in Hologic during the second quarter valued at $907,000. Finally, Geode Capital Management LLC increased its position in Hologic by 54.3% in the first quarter. Geode Capital Management LLC now owns 2,328,326 shares of the company’s stock valued at $80,187,000 after buying an additional 819,646 shares during the period. Institutional investors own 94.51% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.